Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VisEn Medical Inc.

This article was originally published in Start Up

Executive Summary

VisEn Medical's core technology is based on activatable "smart imaging agents" and novel optical systems, including fluorescence-mediated tomography. The ability to visualize reactions and processes in vivo in real time using agents specifically activated by molecular targets, processes, or pathways-the molecular signatures of disease--may lead to breakthroughs that aren't possible with in vitro methods.

You may also be interested in...

Sloan-Kettering Shines a Light on Nanotech Imaging

Researchers at Memorial Sloan-Kettering and Cornell University have taken the first steps toward moving a silica-based nanoparticle platform invented at Cornell into use in cancer imaging. Using optical imaging and PET, they showed that encapsulating a dye in a biocompatible nanoscale matrix enhanced imaging capabilities while maintaining efficient clearance through the urine.

Imaging in its Heyday: Research Applications (Part 1)

Biomolecular imaging is upgrading diagnostic imaging's stodgy reputation as scientists increasingly use it to improve both pharmaceutical research and clinical care. Part I of a two-part series explores researchers' excitement about biomolecular imaging's potential to improve the drug development process. Many companies see research applications as a way to prime the marketplace for clinical applications. But venture capitalists think research is a limited opportunity.

Science Matters: Welcome To The Oncobiome

A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts